[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100601647":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":20,"locations":21,"responsibleParty":57,"collaborators":20,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":20,"eligibilityCriteria":65,"healthyVolunteers":61,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":20,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":20,"overallStatus":24,"whyStopped":20,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Southern College of Optometry","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Qlosi","EXPERIMENTAL","Subjects will be treated with Qlosi™ BID OD\u002FOS, and subjects will only be allowed to use reading glasses for urgent work",[13],"Drug: pilocarpine HCL ophthalmic solution",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","pilocarpine HCL ophthalmic solution","Qlosi will be given to participants and quality of life will be determined.",[9],null,[22,42],{"facility":23,"status":24,"city":25,"state":26,"zip":27,"country":28,"countryCode":29,"cosmosGeoPoint":30,"geoPoint":35,"contacts":36},"Complete Eye Care of Medina","RECRUITING","Medina","Minnesota","55340","United States","US",{"type":31,"coordinates":32},"Point",[33,34],-93.58246,45.03524,{"lat":34,"lon":33},[37],{"name":38,"role":39,"phone":40,"phoneExt":20,"email":41},"Gina Wesley, OD","CONTACT","763-478-3505","leahlang@cecofmedina.com",{"facility":43,"status":24,"city":44,"state":45,"zip":46,"country":28,"countryCode":29,"cosmosGeoPoint":47,"geoPoint":51,"contacts":52},"The Southern College of Optometry","Memphis","Tennessee","38104",{"type":31,"coordinates":48},[49,50],-90.04898,35.14953,{"lat":50,"lon":49},[53],{"name":54,"role":39,"phone":55,"phoneExt":20,"email":56},"Chris Lievens, OD","9014815699","clievens@sco.edu",{"type":58,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100601647","phase-4-quality-of-life-in-presbyopic-patients-who-are-treated-with-qlosi-100601647",false,"NCT07113210","Quality of Life in Presbyopic Patients Who Are Treated With Qlosi","Understanding Quality of Life in Presbyopic Patients Who Are Treated With Qlosi","Inclusion Criteria:\n\n* Subjects who are 45-64 years old (inclusive) at the time of screening.\n* Be able and willing to provide written informed consent and sign a Health Information Portability and Accountability Act (HIPAA) form prior to any study procedure being performed.\n* Be able and willing to follow all instructions and attend study visits.\n* Have text messaging capabilities on their phone.\n* Self-reported complaints of near vision blur when fully corrected at distance.\n* Study confirmed near add that is between +0.75 D to +2.00 D OD\u002FOS (inclusive).\n* Spherical distance prescription between +1.00 D to -4.00 D OD\u002FOS (inclusive).\n* Cylinder power less than or equal to -1.00 D OD\u002FOS.\n* Best-corrected visual acuity (BCVA) at distance of 0.00 logMAR (20\u002F20 Snellen equivalent) or better OD\u002FOS.\n\nExclusion Criteria:\n\n* Known hypersensitivity to any ingredient in the study drops.\n* Any active ocular condition that may confound study results (e.g., dry eye, allergy, conjunctivitis, ocular infection).\n* Any use of prescription eye drops 1 week before screening or during the study.\n* Any past use of the study drops.\n* Any contact lens use for the duration of the study.\n* Artificial tears or lubricant eye drops use on the day of or during any study visits.\n* Clinically significant abnormal findings (e.g., central corneal scar) on a slit lamp exam in either eye documented at screening or a known history of a clinically significant slit-lamp finding in either eye that could confound study results.\n* Have had an ocular surgical intervention within 6 months of the screening visit or planned surgical intervention during the study.\n* A female of childbearing potential who is currently pregnant, nursing, or planning a pregnancy.\n* Any visible retinal findings noted upon a dilated fundus examination known to be a risk for use of study treatment (as determined by the investigator).","ALL","45 Years","64 Years",{"count":70,"type":71},36,"ESTIMATED","INTERVENTIONAL",[74],"PHASE4","The goal of this clinical trial is to determine how Qlosi™ (pilocarpine HCL ophthalmic solution) 0.4%impacts the quality of life of participants with presbyopia by using a battery of validated and investigator-developed instruments\n\n* Improvement in presbyopic symptoms as measured with the Near Activity Visual Questionnaire-Presbyopia (NAVQ-P) when using Qlosi™ at week 4 compared to baseline (continuous variable).\n* Improvement in presbyopic symptoms as measured with the Visual Quality of Life with Time Survey (VisQualT) questionnaire when using Qlosi™ at week 4 compared to baseline.",[77,78,79],"Presbyopia","Glasses","Dry Eye","2025-08-07",{"date":82,"type":83},"2025-08-12","ACTUAL",{"date":85,"type":83},"2025-07-18",{"date":87,"type":71},"2025-11-15",{"name":5,"class":6},2]